NCT05309460 Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
| NCT ID | NCT05309460 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Nebraska Methodist Health System |
| Condition | Postpartum Preeclampsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2022-06-20 |
| Primary Completion | 2024-05-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.
Eligibility Criteria
Inclusion Criteria: Any patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension. Exclusion Criteria: History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema * Contraindication to either Nifedipine or Labetalol * HR \<60 or \>110 * Native language other than English or Spanish